BACKGROUND: Transcobalamin (TC) and haptocorrin (HC) are serum corrinoid-binding proteins. We developed new methods for measurement of the corrinoids bound to HC and TC.
METHODS: TC (n ϭ 10) or HC (n ϭ 138) was immunoprecipitated, and corrinoids were released by enzymatic degradation [subtilisin Carlsberg (EC 3.4.21.62)] of the binding proteins. Binding of the released corrinoids to added unsaturated TC (apoTC) or HC (apoHC) created holoTC (as measure of cobalamins) and holoHC (as measure of corrinoids). holoTC and holoHC were measured by use of ELISA. The amounts of analogs were calculated as the difference between corrinoids and cobalamins. Corrinoids extracted from HC were separated with HPLC after addition of potassium cyanide (n ϭ 3).
RESULTS:
The corrinoid-and cobalamin-specific assays had a positive linear relation between analyte concentration and assay signal, detection limits of 8 and 4 pmol/L, and imprecision values (CV) of Յ10% and Յ13% for concentrations between 45-200 and 12-115 pmol/L, respectively. No analogs were bound to serum TC, whereas the mean (95% reference range) for analogs present on HC was 245 (100 -380) pmol/L. On HPLC a substantial amount of the analogs showed elution patterns similar to those of dicyanocobinamide.
CONCLUSIONS:
Our methods for measurement of unmodified corrinoids in serum demonstrate that HC carries cobalamin analogs not recognized by TC, and that on HPLC a substantial part of these analogs elute similarly to cobinamide.
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The uptake and transport of cobalamin (Cbl, 2 vitamin B 12 ) is facilitated by 3 soluble proteins, all of which have high affinity toward Cbl (K D approximately 6 fmol/L) (1, 2 ) . In the intestine Cbl binds to intrinsic factor (IF), a 50-kDa glycoprotein secreted by the gastric epithelium (3 ) . Transport of Cbl across the apical pole of the ileal epithelium is facilitated by cubam, a receptor complex that internalizes IF-Cbl by endocytosis (4 ) . After lysozomal degradation of IF, Cbl is released and transferred to the circulation. In the circulation Cbl is bound to transcobalamin (TC), a 43-kDa protein that carries about 30% of the circulating Cbl (5 ) . Only this portion of the total circulating Cbl is available for cellular uptake (6 ) . In cells 2 active forms of Cbl, methylcobalamin and 5Ј-deoxyadenosylcobalamin, function as cofactors for methionine synthase and methylmalonylCoA mutase, respectively (7 ). Haptocorrin (HC), a 70-kDa glycoprotein with an unknown function, binds the remaining part of the circulating Cbl (3 ).
In the late 1970s it was suggested that one-third of the apparent Cbl found in plasma was in the form of Cbl analogs, corrinoids unable to serve as cofactors (8 ) , although direct identification of such analogs was never achieved. The affinity for corrinoids other than Cbl varies largely among the 3 Cbl-binding proteins. IF and TC are highly specific toward Cbl, and show a relatively low affinity for other corrinoids, such as cobinamides (K D approximately 5-40 nmol/L), whereas HC binds all corrinoids almost equally well (K D approximately 6 fmol/L) (2 ) . This characteristic has led to the suggestion that HC functions as a scavenger protein that binds Cbl analogs in the circulation and is cleared into the bile via hepatic asialoglycoprotein receptors (9 ) . Interestingly, a few studies have associated high concentrations of Cbl analogs in the circulation with neurologic abnormalities and Alzheimer disease (10, 11 ) . A major question raised regarding the early work on Cbl analogs related to their origin, and it remained unclear to what extent they were created during the extraction procedure needed to liberate the corrinoids before their measurement. We have circumvented this issue in the present work. We used an enzymatic release of the corrinoids from the immunoprecipitated binding proteins, a process that leaves the molecular form of the corrinoids unchanged (12 ) , and combined this technique with a new procedure for measurement of Cbl and corrinoids by use of ELISA. We observed that HC carries corrinoids not recognized by TC and found that a substantial portion of the analogs show an HPLC elution pattern similar to cobinamide.
Materials and Methods

STUDY SAMPLES
Blood samples were obtained from 138 healthy Danish donors in 2004, and the serum or EDTA-plasma stored at Ϫ20°C. The study population, which has been previously characterized (13 ) , consisted of 61 women and 77 men with a median (range) age of 50 (21-64) years. Use of the samples was subject a general agreement between the Association of Blood Donors in Denmark, and the Public Blood Bank (Aarhus University Hospital, Skejby, Denmark), and approved by the Regional Committee on Biomedical Research of Aarhus County.
ASSAYS FOR QUANTIFICATION OF Cbl AND TOTAL CORRINOIDS
Deglycosylation of serum HC and immunoprecipitation and proteolytic degradation of TC and HC were performed as previously described (12 ) . For measurement of corrinoids on TC, 200 L serum was immunoprecipitated with the sediment of 25 L magnetic beads covered with monoclonal antibodies against TC (donated by Axis-Shield, UK). For measurement of corrinoids on HC, 50 L serum was immunoprecipitated with the sediment of 25 L magnetic beads covered with monoclonal antibodies against HC (produced in house). Subsequently, 100 L of subtilisin Carlsberg from Bacillus licheniformis (EC 3.4.21.62, Sigma Aldrich) in 0.1 mol/L TrisHCl (Sigma-Aldrich), pH, 7.4 was added, followed by incubation for 2 h at 37°C. After incubation, 5 L phenylmethanesulfonyl fluoride (Sigma-Aldrich) was added, followed by addition of assay buffer [0.1 mol/L phosphate buffer pH 8, 0.1% bovine albumin (Sigma-Aldrich)] to reach a final volume of 220 L.
Cbl ASSAY
Calibrators ranging from 17-1091 pmol/L were prepared by diluting cyanocobalamin (CNCbl, SigmaAldrich) in assay buffer. The assay buffer was used as a zero calibrator. We incubated 50 L of the calibrators with 100 L subtilisin Carlsberg for 2 h at 37°C. After incubation, 5 L phenylmethanesulfonyl fluoride was added, followed by addition of assay buffer to reach a final volume of 220 L. Because of the dilution, the final concentrations of the calibrators ranged from 4 -242 pmol/L. We then mixed apoTC (unsaturated recombinant TC) (100 L, 350 pmol/L, donated by Cobento A/S, Denmark) in assay buffer with 100 L of samples or calibrators, and incubated the mixture for 30 min at room temperature. The amount of created saturated TC (holoTC) present in the samples and calibrators was measured as previously described (14, 15 ) .
CORRINOID ASSAY
The assay for quantification of total corrinoids in the samples was developed as described for the Cbl assay. Unsaturated HC (apoHC) (750 pmol/L) in assay buffer was prepared from plasma with a more than 10000-fold increase in HC (16 ) . The final concentrations of the calibrators ranged from 8 -484 pmol/L. Measurement of HC saturated with corrinoids (holoHC, corresponding to the amount of total corrinoids in the calibrators/samples) was performed as previously described (17 ) .
LINEARITY, RECOVERY, AND IMPRECISION
Validations of the Cbl assay and the corrinoid assay were done simultaneously with paired measurements of corrinoids released from serum HC. For linearity studies, 4 serum samples were diluted 20%, 40%, 60%, and 80% in assay buffer. For recovery studies, measurements were performed before and after supplementation with 200 pmol/L CNCbl (n ϭ 5). We evaluated the imprecision of the assays by measuring extracts from serum samples containing 3 concentrations of corrinoids (225, 500, and 900 pmol/L) carried on HC. Dilution of the preparations of released corrinoids resulted in solutions with total corrinoid concentrations of 45, 115, and 200 pmol/L and solutions with Cbl concentrations of 12, 50, and 115 pmol/L. The preparations were measured 4 times on each plate on 6 different days over a period of 2 months.
INTERFERING SUBSTANCES
To ensure that protein fragments, or any released substances, did not interfere with the 2 assays, 100 L deglycosylated or native apoHC in the concentration range of 1500 -6000 pmol/L was immunoprecipitated (12 ) . Subsequent treatment with subtilisin Carlsberg and measurements of the extraction solutions were performed as described for the serum samples.
HPLC SEPARATION OF CORRINOIDS AND ANALYSIS OF POSTCOLUMN FRACTIONS
To prepare samples for HPLC, corrinoids released from serum HC present in 1000 L of sample from each of 3 different donors were prepared as described above. Before HPLC separation, the released corrinoids were converted into their cyanide forms by ex-posure to potassium cyanide (KCN, Sigma-Aldrich, 0.1 mol/L in the final solution). Standard solutions containing 200 pmol/L CNCbl or 100 pmol/L dicyanocobinamide (CN 2 Cbi, Sigma-Aldrich) were also exposed to KCN before HPLC.
SEPARATION OF KCN-EXPOSED CORRINOIDS
The corrinoids present in the samples or standards were separated with HPLC essentially as described by Jacobsen et al. (18 ) . The HPLC apparatus (HP 1100, Agilent Technologies) was fitted with a precolumn (SecurityGuard Cartridge, Phenomenex) followed by a reversed-phase column (Luna 3u reversed-phase C18 150 mm ϫ 4.6 mm, Phenomenex), which was maintained at 20°C. A gradient of acetonitrile (J.T.Baker) increasing from 5% to 30% over 20 min in 0.05 mol/L phosphoric acid, pH 5, was applied 4 min after injection of 90 L of samples or standard mixtures, with a flow rate of 1.0 mL/min. Postcolumn fractions were collected for every 30 s between 11 and 22 min after injection, and the eluent in the fractions was lyophilized (Heto-Vac, Denmark). The postcolumn fractions were analyzed using the Cbl assay and the corrinoid assay, and the total amounts of corrinoids present in each fraction were calculated and used to measure the peak areas in the resulting chromatograms.
ANALYSES OF SAMPLES FOR Cbl ANALOGS
To investigate whether the pattern of corrinoids differed between TC and HC, we initially analyzed the corrinoids present on serum TC and HC in 10 serum samples. We used 138 serum samples to establish a reference interval for Cbl analogs on serum HC. Calculation of Cbl analogs in the samples was performed by subtracting the result obtained with the Cbl assay from the result obtained with the corrinoid assay, in paired measurements of corrinoids released from either TC or HC. All handling of serum and material obtained from serum was done in 2-mL polypropylene tubes (Sarstedt), except for material prepared for HPLC separation, which was handled in 200-L polypropylene conic vials (Microlab).
OTHER METHODS
The amounts of holoTC present in serum and holoHC present in plasma were analyzed as previously described (15, 17 ) . Total Cbl was analyzed by use of a Centaur Analyzer (Siemens) employing the analytical kit supplied by the manufacturer. The assay employs intrinsic factor as the binding protein. Data for total HC and total Cbl in plasma have previously been published (13 ).
STATISTICAL ANALYSIS
All statistical analyses (linear regression and paired and unpaired t-tests) were performed with the software program Intercooled Stata version 9.0 (Stata Corp).
Results
ASSAY PERFORMANCE FOR Cbl AND CORRINOID ASSAYS
Representative calibration curves for the Cbl assay and the corrinoid assay are shown in Fig. 1A . The analytical characteristics of the assays are summarized in Table 1 and briefly presented below.
LINEARITY
Four serum samples were analyzed undiluted and in serial dilutions of 20%, 40%, 60% and 80%. The results obtained for the samples diluted to 40% were used only to calculate the expected concentrations in the samples. The calculated expected concentrations were plotted against the measured values (Fig. 1B) . Both assays showed linearity with a slope and an intercept not significantly different from 1 and 0.0, respectively.
RECOVERY
We determined the analytical recovery for both assays by subtracting the value for the unsupplemented sample (n ϭ 5) from the value for the samples supplemented with CNCbl, and dividing this value by the amount of added CNCbl (200 pmol/L). The percentage recovery was calculated by multiplying this result by 100, yielding values that ranged between 94%-110% for the Cbl assay and 97%-100% for the corrinoid assay.
LIMITS OF DETECTION AND LOWER LIMITS OF QUANTIFICATION
We defined the limits of detection for the 2 assays as the 3 SDs above the mean concentrations of the zero calibrators (measured in duplicates, n ϭ 11). For the Cbl assay (corrinoid assay) a detection limit of 3.7 pmol/L (5.1 pmol/L) was obtained, but for practical reasons we used the lowest calibrator concentration of 4 pmol/L (8 pmol/L). The lower limit of quantification, defined as the concentration with a total imprecision Յ20%, was found to be 10 pmol/L (19 pmol/L) for the Cbl assay (corrinoid assay). These concentrations were measured in duplicate (n ϭ 11).
IMPRECISION
For the Cbl assay, the intraassay imprecision (total imprecision) values were 6%-11% (8%-13%). For the corrinoid assay the intraassay imprecision (total imprecision) values were 5%-8% (8%-10%).
INTERFERING SUBSTANCES
We observed no interference when we analyzed the protein fragments released from immunoprecipitated native and deglycosyated samples of apoHC (500 -6000 pmol/L) exposed to proteolytic degradation (n ϭ 6). The results obtained were below the detection limits of the assays.
CORRINOIDS ON SERUM TC AND HC
In our initial search for Cbl analogs on HC and TC, we analyzed corrinoids released from serum TC and HC in samples from 10 healthy donors (Fig. 2) . The corrinoids released from TC showed no difference when measured with the Cbl assay and the corrinoid assay (paired t-test, P ϭ 0.1). In the same samples, corrinoids released from HC showed considerably higher values when measured with the corrinoid assay than when measured with the Cbl assay (paired t-test, P Ͻ 0.0001). These results suggest that HC carries a substantial amount of Cbl analogs.
The reference interval for Cbl analogs present in serum was based on measurements of corrinoids released from serum HC from samples obtained from 138 healthy donors. The 95% reference range (mean) was 100 -380 (245) pmol/L. The results showed a strong association to total HC (Fig. 3A, linear There was no significant difference in the concentration of analogs related to sample donor sex (unpaired t-test, P ϭ 0.88) or age (linear regression test, P ϭ 0.36). Almost half (30%-75%, mean ϭ 52%) of the total amount of corrinoids attached to serum HC was accounted for by analogs, and the analogs accounted for 18%-67% (mean ϭ 44%) of the total amount of corrinoids present in serum.
COMPARISON OF VARIOUS MEASURES OF CIRCULATING
CORRINOIDS
We compared the results on corrinoids released from circulating HC, and measured with the corrinoid assay, with the results obtained for circulating holoHC measured with ELISA (Fig. 4A) . As expected, a strong association was observed (linear regression test, P Ͻ 0.0001; 95% CI for the slope of the linear regression line, 0.91-1.14). We also compared our estimate for total circulating Cbl, which was calculated as the sum of holoTC and HC-Cbl (corrinoids released from serum HC and measured with the Cbl assay) with measurement of total circulating Cbl with routine assay (Fig. 4B) . A strong linear association was observed (linear regression test, P Ͻ 0.0001; 95% CI for the slope of the linear regression line;, 0.82-1.00).
HPLC INVESTIGATIONS OF Cbl ANALOGS
Combined with HPLC, the low limits of detection of the Cbl assay and the corrinoid assay enabled further characterization of the Cbl analogs. Corrinoids were released from serum TC (A) or HC (B) in samples from 10 healthy donors, and measured with the Cbl-assay (E) and the corrinoid assay (F). A significant difference between the 2 measurements was observed for the corrinoids released from HC, whereas this was not the case for corrinoids released from TC.
Fig. 3. Comparison of Cbl analogs on serum HC.
Comparison of Cbl analogs on serum HC with (A), total HC, and (B), total Cbl. When the 2 extreme points in each plot (marked with ϫ) were omitted, the correlation in (A) was still significant (P Ͻ 0.0001), whereas the correlation in (B) was not (P ϭ 0.36). Samples from 138 healthy donors were examined.
First we characterized the elution profiles of KCNtreated calibrators of CN 2 Cbi and CNCbl. CN 2 Cbi eluted as 1 distinct peak at 16.5 min (detected with the corrinoid assay but not the Cbl assay), whereas CNCbl eluted with a major peak at 15 min (detected with both the Cbl and the corrinoid assay) and a minor broader peak at 21-21.5 min (detected only with the corrinoid assay) (Fig. 5A) . The peak at 21-21.5 min is presumably the dicyanoform of Cbl (CN 2 Cbl).
Next, for 3 donor samples we analyzed the corrinoids released from HC and treated with KCN (Fig. 5B,  5C , and 5D). All 3 samples showed a major peak with retention time at 15 min and a minor broader peak at 19.5 min that were recognized equally well with the Cbl and the corrinoid assay. These 2 peaks (likely representing CNCbl and decomposed CN 2 Cbl) accounted for 52%, 51%, and 58% of the total amount of corrinoids detected, respectively (calculations based on peak areas). The corrinoids detected only with the corrinoid assay and not seen in the chromatogram of the KCN-exposed standards eluted as 3 peaks with retention times 13.5-14, 16.5, and 18.5-19 min. The peak eluting at 16.5 min (eluting as does CN 2 Cbi) accounted for 45%, 47%, and 32% of the analogs detected in each of the 3 runs, respectively. Recoveries of the total amounts of corrinoids detected in the 3 sample chromatograms were 90%, 82%, and 83%, respectively.
Discussion
We used the assays described here to show that serum HC carries forms of corrinoids (the so called Cbl analogs) not recognized by TC, and we demonstrated that on separation with HPLC a substantial amount of the analogs elute as does cobinamide.
Our new methods take advantage of the enzymatic liberation of unmodified corrinoids from immunoprecipated TC and HC (12 ) . On addition to the released corrinoids of apoTC (for measurement of Cbls) or apoHC (for measurement of the total amount of corrinoids), holoTC or holoHC can be measured by using established ELISAs (15, 17 ) . The assays have 2 advantages. First, the pretreatment of the samples is far gentler than the currently used procedures employing extreme pH (19 ) . Second, our assay design allows a direct linear relationship between the signal and the concentration of corrinoid, resulting in a detection limit Ͻ10 pmol/L. In contrast, commercial Cbl assays, which use competition for binding to intrinsic factor, show a nonlinear negative correlation between the signal and the concentration of Cbl and have detection limits well above 10 pmol/L.
Cobalamin analogs in the circulation were first identified in the late 1970s (8 ) . At that time, studies of Cbl analogs in biological samples were based on extraction procedures that involved acidic or alkaline solutions, addition of KCN, and sometimes heating before quantification of the corrinoids with radioisotope dilution assays (20, 21 ) . There has been discussion as to whether these extraction procedures could alter the molecular form of Cbl, thereby creating the Cbl analogs as artifacts (22, 23 ) . We have circumvented this problem by using an enzymatic degradation of the binding proteins, thereby ensuring that Cbl analogs observed are not caused by the extraction procedure (12 ) .
Our suggested 95% reference range of 100 -380 pmol/L for Cbl analogs on HC agrees with studies done by Allen and coworkers (8 ) , who found the reference range to be 50 -450 pmol/L (n ϭ 74) when analyzing corrinoids released from plasma employing an acidic extraction procedure, combined with addition of KCN and heating. Our data therefore strongly support the presence of genuine analogs not caused by the extraction procedures. The comparability of results obtained whether IF (Allen et al.'s work) or TC (present study) was used for estimation of Cbl suggests that serum does not contain corrinoids recognized by TC but not by IF.
The amount of analogs present on serum TC and HC has, to our knowledge, not been reported previously. As expected, we did not observe any difference in the amounts of Cbl or corrinoids measured for corrinoids released from TC, whereas a marked difference was observed for corrinoids released from HC. Almost half of the total corrinoids attached to HC were Cbl analogs, and the analogs constituted a little less than one-half of the total amount of corrinoids present in the circulation. These results agree well with our previous attempt to estimate the amounts of analogs attached to HC by calculating holoHC minus HC-Cbl, where HC-Cbl was defined as total Cbl minus holoTC. Using this method, we found that Cbl analogs account for about 40% of all corrinoids on HC in non-Cbldeficient donors, and about 60% of all corrinoid on HC among Cbl-deficient patients (24 ) .
Because HC degrades with a fractional catabolic rate of approximately 0. 15/d (25 ) , the estimated daily clearance of analogs on HC is on the order of 170 pmol (0.23 g). This calculation is based on an estimated plasma volume of 2.5 L, a distribution ratio of 0.56 (25 ) , and a mean analog concentration of 245 pmol/L. The estimated turnover of analogs is approximately 10% of the daily requirement of vitamin B 12 of 2.4 g (26 ) . Interestingly, we observed a strong correlation between the total amount of HC and the amount of analog present in serum. In that aspect the analogs seem to behave as does total serum Cbl (13, 27 ) . At present we have no explanation to offer for this observation.
Our strategy combining immunoprecipitation of HC with an enzymatic release of the corrinoids allowed us to both concentrate the corrinoids and to have them in a solution free of most other substances in serum, which allowed analysis using HPLC. We analyzed samples not protected from daylight, spiked with KCN, to ensure that the axial ligands of the corrinoid were CN. With this approach we collected all native Cbl in 1 peak, and avoided peaks from the different forms of Cbl that mask the peaks of the analogs. As expected, around half of the corrinoid present in the samples coeluted with CNCbl, and was recognized equally well with the Cbl and the corrinoid assay. A minor peak in the samples was observed at 21-21.5 min that coeluted with a minor peak also occurring when CNCbl was exposed to KCN. This peak was recognized only by the HC-corrinoid assay and is most likely a dicyanoform of Cbl. In addition we observed 3 peaks that were considerably more recognizable with the corrinoid assay than with the Cbl assay. We do not know the nature of all of these peaks, but 1 eluted as did KCN-exposed CN 2 Cbi at 16.5 min, and this peak constituted more than onethird of the Cbl analogs detected with this method.
The origin of the observed analogs is unknown. We doubt that they originate from passive absorption from the intestine, because the pattern of analogs detected on HC differs markedly from what has been observed in human feces (28 ) . Although around one-third of the analogs on HC are classified to be cobinamide, feces contain Ͻ2% cobinamide (28 ) . We find it more likely that the circulating Cbl analogs are produced in the body, possibly by hydrolysis of the phosphate bond that links the corrin ring structure of Cbl to the ribofuranose unit. Future studies are needed to clarify this issue.
